case_images: PMC10551165_01
case_images: Rapid response to anifrolumab in patients with CLE. (A) CLASI-A scores in patients with SLE before and during anifrolumab treatment. (B) DLQI during treatment. (C) SCLE and CDLE lesions rapidly responding to anifrolumab treatment. (D) IFN score during treatment. qRT-PCR of PBMCs was performed to measure the expression of seven individual genes (IFI27, IFI44, IFI44L, IFIT1, ISG15, SIGLEC1, and RSAD2) normalized to GAPDH and HPRT1 and compared to a cohort of healthy controls. The score is calculated as previously described. A negative score is defined as <12.49 (mean ISG score of 10 controls plus two SD), and graphs show mean and SD. Unpaired Student's t-test, **p < 0.01, *p < 0.05. (E) Mean decline of IFN and CLASI scores in all patients over time.
case_images: fimmu-14-1253279-g001.jpg
case_images: PMC10551165_01_fimmu-14-1253279-g001.jpg
case_images: f1
case_images: Previously refractory skin lesions were improved by 50% after 1 month as measured by median CLASI - activity (CLASI-A) and nearly completely resolved within 3-12 months of treatment ( Figures 1A, C ). Importantly, this clinical response was seen in all subtypes of cutaneous lupus and even chronic discoid lesions rapidly responded to treatment ( Figure 1C ,  Table 1 ). Relief of cutaneous symptoms was associated with improvement in quality of life ( Figure 1B ). IFN scores in blood ( Figures 1D, E ). IFN scores continued to decline over 6 to 12 months of treatment. Our data reveal that IFN scores in contrast to CLASI-A did not completely resolve during therapy in most of the patients ( Figure 1E ).